Shopping Cart - CHF 0.00

You have no items in your shopping cart.

  • Home  » 
  • 4039778
Return to Previous Page

Promobanner OCT 2020

4039778

Availability: In stock

Acetyl-(Nle⁴,Asp⁵,D-Phe⁷,Lys¹⁰)-cyclo-α-MSH (4-10) amide acetate salt
Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys-NH₂) acetate salt

4039778

Product No. Pack Size Available ADS InfoAnalytical Data Sheet List Price Online Order Price Qty
4039778.0001 1 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 105.00
CHF 97.65 (7%)
4039778.0005 5 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 420.00
CHF 390.60 (7%)

Details

Melanotan II, a cyclic MSH analog, is a potent full agonist of the melanocortin-3 and melanocortin-4 receptors (MC3-R and MC4-R). Intracerebroventricular administration of MTII inhibited feeding in four different mouse models of hyperphagia. MTII is a valuable tool for the study of the agouti obesity syndrome and of the role of melanocortinergic neurons in feeding.
Catalog Number H-3902
APC Number 68-1-30
Synonyms MTII, (Ac-Nle4, Asp5, DPhe7, Lys10)-Cyclo-a-MSH (4-10) amide, Melanotan II, Bremelanotide amide
Molecular Formula C₅₀H₆₉N₁₅O₉
Relative Molecular Mass 1024.19
CAS Registry Number 121062-08-6
Source Synthetic
Storage Conditions -20 ± 5 °C
Application Cancer Research
Cosmetic Peptides & Dermatology
Obesity Research
Pituitary & Hypothalamic Hormones
Links / Documents:

Bachem product citations

A.Yavari et al., Cell Metab., 23, 821 (2016)
S.Rossi et al., Mediators Inflamm., 2016, 7368389 (2016)
B.Lute et al., Cell Metab., 20, 333 (2014)
H.Pei et al., Mol. Metab., 3, 209 (2014)
K.Nohara et al., Obesity (Silver Spring), 22, 1477 (2014)
S.Veiksina et al., Biochim. Biophys. Acta, 1838, 372 (2014)
H.Cui and M.Lutter, Genes Brain Behav., 12, 658 (2013)
J.W.Sohn et al., Cell, 152, 612 (2013)
P.Li et al., Exp. Physiol., 98, 435 (2013)
Y.Xu et al., Cell Metab., 18, 860 (2013)
C.Blouet and G.J.Schwartz, Cell Metab., 16, 579 (2012)
C.Blouet et al., J. Neurosci., 32, 9870 (2012)
H.Cui et al., J. Comp. Neurol., 520, 4168 (2012)
S.K.Billes et al., Mol. Metab., 1, 86 (2012)
Z.Wu et al., PLoS One, 7, e45167 (2012)
A.Leckstrom et al., Neuropeptides, 45, 123 (2011)
A.Leckstrom et al., Life Sci., 88, 664 (2011)
B.G.Irani et al., Eur. J. Pharmacol., 660, 80 (2011)
Y.Cao et al., PLoS One, 6, e18324 (2011)
J.C.Chuang et al., Biol. Psychiatry, 67, 1075 (2010)
D.Li and A.W.Taylor, J. Leukoc. Biol., 84, 191 (2008)
J.Y.Altarejos et al., Nat. Med., 14, 1112 (2008)
I.Melnick et al., Neuron, 56, 1103 (2007)
M.Claret et al., J. Clin. Invest., 117, 2325 (2007)
C.R.Abbott et al, Int. J. Obes. (Lond.), 30, 288 (2006)
E.U.Do et al., Biochem. Biophys. Res. Commun., 343, 1094 (2006)
Z.Xiang et al., Biochemistry, 45, 7277 (2006)
D.Flora et al., Bioorg. Med. Chem. Lett., 15, 1065 (2005)
D.Flora et al., Bioorg. Med. Chem. Lett., 15, 1065 (2005)
F.Giuliano et al., Eur. Urol., 48, 145 (2005)
N.Balthasar et al., Cell, 123, 493 (2005)
R.L.Bradley et al., Obes. Res., 13, 653 (2005)
A.N.van den Pol et al., Neuron, 42, 635 (2004)
A.Wilczynski et al., J. Med. Chem., 47, 2194 (2004)
M.Doghman et al., Endocrinology, 145, 541 (2004)
W.A.Nijenhuis et al., Eur. J. Pharmacol., 495, 145 (2004)
W.A.Nijenhuis et al., Eur. J. Pharmacol., 495, 145 (2004)
C.G.Joseph et al., Peptides, 24, 1899 (2003)
S.J.Getting et al., J. Pharmacol. Exp. Ther., 306, 631 (2003)
C.Polidori and N.Geary, Peptides, 23, 1697 (2002)
R.Thirumoorthy et al., J. Med. Chem., 44, 4114 (2001)

Product citations

W.Fan et al., Nature, 385, 165 (1997)
V.J.Hruby et al., J. Med. Chem., 38, 3454 (1995)